More Prostate Cancer Patients Choose Surveillance
Men are increasingly opting to put off treatment for low-risk prostate cancer, and doctors say it’s a good thing.
Progress Against Cancer
Men are increasingly opting to put off treatment for low-risk prostate cancer, and doctors say it’s a good thing.
Mammography screening recommendation pushed back to age 40, and pancreatic cancer vaccine shows promising immune response.
An increased risk of early death exists even after treatment for childhood cancer, but survivors also have the potential for decades of life after cancer.
Researchers discover a new way breast density can impact cancer risk, and CAR T-cell therapy remains out of reach for patients with HIV.
The AACR Annual Meeting 2023 set a new record this year with the number of clinical trial abstracts submitted to the meeting. More than 240 abstracts were showcased over the course of the meeting...
Although not common, a cancer diagnosis during pregnancy or the onset of a pregnancy while a woman is receiving anticancer treatment poses unique challenges. The Presidential Select Symposium at the AACR Annual Meeting 2023...
Earlier this month, over 21,000 researchers, clinicians, patients, and other stakeholders gathered at the AACR Annual Meeting 2023 to discuss the latest advances across the continuum of cancer research—from basic science to clinical research...
More programs address sexual health in cancer survivors, and survey suggests health insurance often doesn’t cover genetic tumor testing.
Historically, most cancer drugs have been tested separately in adults and children. For the approval of new drugs for children, researchers must ensure that doses are properly recalculated and new side effects do not...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in the plenary hall and virtually to watch the Opening Plenary Session of the AACR Annual...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More